Savara, Inc.

As of September 19, 2025, Savara, Inc. shows a mildly bullish trend with mixed signals from MACD indicators and moving averages, having outperformed the S&P 500 recently but underperformed over the past year.

As of September 12, 2025, Savara, Inc. has shifted to a bullish technical trend, supported by a bullish weekly MACD and daily moving averages, despite bearish signals on the monthly MACD and KST, while outperforming the S&P 500 with an 18.03% return over the past month.

As of June 13, 2025, Savara, Inc. is in a bearish trend, indicated by negative MACD, moving averages, and Bollinger Bands across multiple time frames, along with significant negative returns compared to the S&P 500.

As of March 2022, the management team of Savara, Inc. includes Mr. Matthew Pauls as Chairman and CEO, along with independent directors Mr. Nevan Elam, Mr. Richard Hawkins, Dr. Joseph McCracken, Mr. David Ramsay, and Mr. Ricky Sun.

Savara, Inc. is a pharmaceutical company focused on developing and commercializing treatments for orphan lung diseases. As of March 2025, it has a market cap of $352.59 million and reported a net profit loss of $27 million.

As of Jun 18, Savara, Inc. has a market capitalization of 352.59 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -102.17 million over the latest four quarters. As of Dec'24, the company reported shareholder's funds of 171.45 million and total assets of 212.88 million.